

TDF/3TC/DTG (TENOFOVIR DISOPROXIL/LAMIVUDINE/DOLUTEGRAVIR)



- 14 MPP licensees are currently developing TDF/3TC/DTG, of which:
 - Seven have filed with WHO-PQ
 - Seven have filed with USFDA; of which **Aurobindo**, **Hetero** and **Mylan** have received approvals
- Cipla, Hetero, Macleods, and Sun have received ERP approval
- In all, <u>three generic versions of TLD</u> are already in the market and an additional three are expected to be launched soon



TDF/3TC/DTG: country-wise filing status

Approved (6)

(19.4% PLHIV in LMICs)

Botswana

Côte d'Ivoire

India

Kenya

Malawi

Uzbekistan

Filed (25) (69.2% PLHIV in LMICs)		
Benin	Ghana	South Africa
Burkina Faso	Madagascar	Tanzania
Burundi	Mali	Uganda
Cameroon	Mozambique	Ukraine
Congo	Namibia	Vietnam
DR Congo	Niger	Zambia
El Salvador	Nigeria	Zimbabwe
Ethiopia	Rwanda	
Gabon	Senegal	

Generic TLD has been filed in 31 countries, of which approval is received from six Another 25 filings are planned for 2018 (covering an additional 7.7% PLHIVs in LMICs)